On the morning of February 7th, the High-Quality Development of industries and Investment Promotion Conference of Shaoguan City was held in the urban area. At the conference, biopharmaceutical projects such as Burke Bio, Daze Nong Bio, and Shude Agriculture were signed in a concentrated manner. A batch of high-quality enterprises have successively settled in Shaoguan and flourished, promoting the further strengthening of the biopharmaceutical industry chain in Shaoguan City and providing strong industrial support for the high-quality economic development of the entire city

Subsequently, an immediate investment promotion and matchmaking conference for the biopharmaceutical industry in Shaoguan City was held to showcase the distinctive advantages, industrial platforms, policy environment and bright prospects of Shaoguan's biopharmaceutical industry, catalyzing in-depth dialogues among multiple parties and exploring new paths for win-win cooperation. Nearly 80 experts, entrepreneurs and representatives of industry associations from various fields of the biopharmaceutical industry across the country gathered together. Fang Wei, member of the Party Group and deputy director of the Guangdong Provincial Drug Administration, and Li Zaifeng, vice mayor of Shaoguan City, attended the meeting.

At the meeting, Li Zaifeng extended a warm welcome to the guests present. He pointed out that in recent years, our city has regarded the biopharmaceutical industry as a strategic emerging industry to be cultivated and developed as a priority. Through "provincial and municipal co-construction", we have innovated the supervision and service for raw material drug enterprises, accelerated the efficiency of project review and approval for key enterprises, and created first-class conditions for the development of the biopharmaceutical industry. During the investment promotion session of the biopharmaceutical industry, Li Zaifeng comprehensively introduced the current development status and broad prospects of the biopharmaceutical industry in Shaoguan City, as well as a series of supportive measures implemented by the government to promote this industry. He sincerely invited all entrepreneurs to visit and inspect Shaoguan, invest and start businesses, and jointly explore development opportunities.

Fang Wei highly affirmed the development achievements of the biomedicine industry in Shaoguan at the meeting. He pointed out that as one of the important biomedicine industrial bases in Guangdong Province, Shaoguan has, in recent years, relied on its abundant natural resources, complete industrial supporting facilities and favorable policy environment to initially build an industrial cluster covering the planting, processing and biological products of Chinese medicinal materials, and has actively introduced and cultivated a number of innovative biomedicine enterprises. Projects such as the raw material drug bases of Yipinhong and Ruidelin have injected new vitality into the Guangdong biopharmaceutical industry to make up for the shortage of raw material drugs. Fang Wei hopes that Shaoguan will closely seize this opportunity, leverage its own industrial advantages, improve and perfect the policy support system for the entire industrial chain, actively cultivate a number of innovative private enterprises with international influence, build a first-class domestic high-end biomedicine industrial cluster, and contribute more demonstration experiences to the high-quality development of Guangdong's biomedicine industry.

During the exchange and speech session of enterprise representatives, many enterprises shared their investment experiences and cooperation visions in Shaoguan, and highly recognized the investment environment and the development prospects of the biopharmaceutical industry in Shaoguan. "Thanks to the trust and support given by Shaoguan City, our enterprise, in collaboration with Shenzhen Guiding Fund Investment Co., Ltd. and Shaoguan Industrial Investment Mother Fund Partnership Enterprise, jointly initiated a 1.5 billion yuan cell and gene synthetic biology industry fund." " Zhang Chong, a partner of Shenzhen Songhe Capital Management Co., LTD., said that Shaoguan has about 5,000 mu of contigualized Class III industrial land, which is scarce in the province. The cost is economical, and the price advantages of key elements such as electricity, green energy and steam are obvious. This provides a key carrier for enterprises to achieve integrated development from upstream to downstream raw materials and preparations.

　In recent years, Shaoguan has seized the development opportunities of the biopharmaceutical industry, actively leveraged its ecological environment advantages as a "natural medicine repository" with a forest coverage rate of 74.59% and over 700 common medicinal plants, accounting for approximately 40% of the province's total medicinal plants, and introduced a series of industrial support measures. Plan and construct the Gantang Industrial Park in Shaoguan High-tech Zone, Wengyuan Innovative Raw Material Medicine Technology Industrial Park, Nanxiong Plant Protection Industrial Park, Ruyuan Big Health Industrial Park and other "1+6" platforms to receive the orderly transfer of industries at a high starting point. At present, the city's biopharmaceutical industry involves multiple sub-sectors such as chemical raw materials, chemical preparations, traditional Chinese patent medicines, biological products, medical devices, and cosmetics, forming a relatively complete biopharmaceutical industrial chain. As the main responsible unit of the biomedicine and health industry chain, the Market Supervision and Administration Bureau of Shaoguan City has been shouldering the responsibility of coordinating safety and development in recent years. It has fully leveraged the strategic cooperation framework agreement between the Provincial drug regulatory authority and the Shaoguan Municipal Government, actively coordinated relevant departments to make good and flexible use of policies, and coordinated to solve key and common problems in the production process of enterprises, promoting the transformation and mass production of scientific and technological achievements in Shaoguan. Up to now, there are a total of 44 key projects under follow-up in the city's biomedicine and health industry chain, with a total investment of 10.33 billion yuan. Since 2024, nine high-quality projects introduced to Shaoguan, including Ruishi Pharmaceutical, Langsheng Pharmaceutical, and Hongtu Biotechnology, have been put into trial production. Ruidelin Biology has successfully settled in Wengyuan, marking an important step forward for Shaoguan in the field of innovative apis.